| Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment AB Kimball, GBE Jemec, M Yang, A Kageleiry, JE Signorovitch, MM Okun, ... British Journal of Dermatology 171 (6), 1434-1442, 2014 | 239 | 2014 |
| Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the … E Swallow, J Zhang, D Thomason, RD Tan, A Kageleiry, J Signorovitch Current medical research and opinion 30 (8), 1537-1545, 2014 | 70 | 2014 |
| State‐level unemployment and the utilization of preventive medical services N Tefft, A Kageleiry Health services research 49 (1), 186-205, 2014 | 46 | 2014 |
| Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons D Wolf, M Skup, H Yang, E Faust, A Kageleiry, J Chao, M Lebwohl JOURNAL OF CROHNS & COLITIS 9, S331-S331, 2015 | 38 | 2015 |
| Out‐of‐pocket medical costs and third‐party healthcare costs for children with Down syndrome A Kageleiry, D Samuelson, MS Duh, P Lefebvre, J Campbell, BG Skotko American journal of medical genetics Part A 173 (3), 627-637, 2017 | 35 | 2017 |
| Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia Y Young-Xu, MS Duh, E Muser, M DerSarkissian, E Faust, A Kageleiry, ... The Journal of clinical psychiatry 77 (10), 13732, 2016 | 25 | 2016 |
| ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer A Guérin, M Sasane, J Zhang, AR Macalalad, P Galebach, J Jarvis, ... Cancer epidemiology 39 (3), 307-312, 2015 | 23 | 2015 |
| Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study J Cadranel, K Park, O Arrieta, M Pless, E Bendaly, D Patel, M Sasane, ... Lung Cancer 98, 9-14, 2016 | 21 | 2016 |
| The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas AR Macalalad, M McAuliffe, H Yang, A Kageleiry, Y Zhong, EQ Wu, ... Current Medical Research and Opinion 31 (3), 537-545, 2015 | 14 | 2015 |
| Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe M Campone, H Yang, E Faust, A Kageleiry, JE Signorovitch, J Zhang, ... Journal of medical economics 17 (12), 837-845, 2014 | 14 | 2014 |
| Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy Y Hao, N Li, AP Fang, V Koo, M Peeples, A Kageleiry, EQ Wu, A Guérin Advances in therapy 33 (6), 983-997, 2016 | 10 | 2016 |
| Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy Y Hao, N Li, AP Fang, V Koo, M Peeples, A Kageleiry, EQ Wu, A Guérin Advances in therapy 33 (6), 983-997, 2016 | 10 | 2016 |
| The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute … FE Nicolini, GW Basak, DW Kim, E Olavarria, J Pinilla-Ibarz, JF Apperley, ... Blood 126 (23), 480, 2015 | 10 | 2015 |
| Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2-metastatic breast cancer: a retrospective US claims study A Guerin, Y Hao, D Tang, M Peeples, A Fang, A Kageleiry, V Koo, N Li, ... Expert Opinion on Pharmacotherapy 17 (9), 1189-1196, 2016 | 7 | 2016 |
| Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast … N Li, Y Hao, A Kageleiry, M Peeples, A Fang, V Koo, EQ Wu, A Guérin Current Medical Research and Opinion 32 (2), 385-394, 2016 | 7 | 2016 |
| Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast … N Li, Y Hao, A Kageleiry, M Peeples, A Fang, V Koo, EQ Wu, A Guérin Current Medical Research and Opinion 32 (2), 385-394, 2016 | 7 | 2016 |
| Characteristics and outcomes of ALK+ non‐small cell lung cancer patients in Korea SH Lim, KA Yoh, JS Lee, M Ahn, YJ Kim, SH Kim, J Zhang, D Patel, ... Asia‐Pacific Journal of Clinical Oncology 13 (5), e239-e245, 2017 | 6 | 2017 |
| Public health impact of Rotarix vaccination among commercially insured children in the United States G Krishnarajah, A Kageleiry, C Korves, P Lefebvre, MS Duh Vaccine 35 (37), 5065-5072, 2017 | 4 | 2017 |
| FRI0123 clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons M Lebwohl, M Skup, H Yang, E Faust, A Kageleiry, J Chao, D Wolf Annals of the Rheumatic Diseases 74 (Suppl 2), 465-465, 2015 | 4 | 2015 |
| Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or … N Li, Y Hao, V Koo, A Fang, M Peeples, A Kageleiry, EQ Wu, A Guérin Journal of Medical Economics 19 (4), 414-423, 2016 | 3 | 2016 |
Darren ThomasonMassachusetts Institute of TechnologyVerified email at iterativehealth.com
